A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2027, filed Nov 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IMNN SEC filings page.
This page shows Imunon, Inc. (IMNN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The company remains development-stage: losses and cash use narrowed, but the latest balance sheet shows heavier claims against equity.
The net loss narrowed from$35.9M in FY2022 to$14.5M in FY2025, while operating cash flow also improved from-$23.1M to-$13.9M . In FY2025, free cash flow of-$14.2M remained close to operating cash flow, indicating that the reported improvement reflected lower operating cash use rather than a large accounting-only adjustment.
FY2022 revenue of only
The latest balance-sheet shift is pronounced: liabilities increased
Financial Health Signals
We do not publish a peer-relative financial health score for Imunon, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Imunon, Inc.'s EBITDA was -$3.4M in Q3 2027, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Imunon, Inc. reported a net loss of $3.8M in Q3 2027. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Imunon, Inc. earned -$0.64 per diluted share (EPS) in Q3 2027. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2027.
Cash & Balance Sheet
Imunon, Inc. recorded an outflow of $3.2M in free cash flow in Q3 2027, representing a cash shortfall after capex.
Imunon, Inc. held $4.0M in cash against $4.9M in long-term debt as of Q3 2027.
Not reported for Q3 2027.
Margins & Returns
Imunon, Inc.'s quarterly ROE was -143.0% in Q3 2027: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is down 75.8 percentage points.
Not reported for Q3 2027.
Not reported for Q3 2027.
Not reported for Q3 2027.
Capital Allocation
Imunon, Inc. invested $1.8M in research and development in Q3 2027. Against the prior quarter it is up 22.4%.
Imunon, Inc. invested $2K in capex in Q3 2027, funding long-term assets and infrastructure.
Not reported for Q3 2027.
IMNN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2710-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.8M | $1.5M+19.4% | $2.3M+8.0% | $2.5M+11.5% | $1.9M-42.3% | $1.2M-56.5% | $2.2M-34.3% | $2.2M-37.2% |
| SG&A Expenses | $1.7M | $1.3M-13.9% | $2.0M-0.6% | $1.8M-7.4% | $1.6M-5.5% | $1.5M-29.8% | $2.0M+15.3% | $1.9M-20.8% |
| Operating Income | -$3.4M | -$2.8Mn/m | -$4.3Mn/m | -$4.3Mn/m | -$3.5Mn/m | -$2.8Mn/m | -$4.1Mn/m | -$4.1Mn/m |
| EBITDA | -$3.4M | -$2.7Mn/m | -$4.2Mn/m | -$4.2Mn/m | -$3.4Mn/m | -$2.7Mn/m | -$4.1Mn/m | -$4.1Mn/m |
| Interest Expense | $264K | $77K | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.8M | -$2.8Mn/m | -$4.2Mn/m | -$4.2Mn/m | -$3.4Mn/m | -$2.7Mn/m | -$4.1Mn/m | -$4.1Mn/m |
| EPS (Basic) | -$0.64 | -$0.54 | -$0.84 | -$1.30 | -$1.16 | -$2.15 | -$3.15 | -$3.45 |
| EPS (Diluted) | -$0.64 | -$0.54 | -$0.84 | -$1.30 | -$1.16 | -$2.15 | -$3.15 | -$3.45 |
| Diluted Shares (Avg) | 6M | 5M | 5M | N/A | 3M | 1M | 1M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
IMNN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2710-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.0M | $15.0M+70.6% | $8.0M+16.9% | $12.3M+26.5% | $9.0M-37.5% | $8.8M-9.3% | $6.9M-52.1% | $9.7M-55.7% |
| Current Assets | $5.8M | $8.7M+26.1% | $6.6M+30.0% | $10.7M+33.9% | $7.3M-42.1% | $6.9M-9.9% | $5.1M-57.9% | $8.0M-56.1% |
| Cash & Equivalents | $4.0M | $6.9M+45.2% | $4.8M+66.9% | $8.8M+49.5% | $5.3M-49.1% | $4.7M-10.9% | $2.9M+22.4% | $5.9M+0.6% |
| Short-Term Investments | $0 | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% |
| Accounts Receivable | N/A | N/A | N/A | $0n/m | N/A | N/A | N/A | $0n/m |
| Long-Term Investments | $0 | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $9.4M | $10.8M+76.2% | $4.7M-27.3% | $5.2M-4.5% | $4.9M-20.9% | $6.1M+3.0% | $6.4M+10.0% | $5.5M-35.8% |
| Current Liabilities | $4.2M | $4.8M-10.1% | $4.2M-28.1% | $4.6M-3.4% | $4.2M-22.9% | $5.3M+4.7% | $5.8M+20.3% | $4.8M-35.2% |
| Non-Current Liabilities | $5.1M | $6.0M+642.3% | $493K-19.6% | $602K-12.3% | $708K-6.5% | $811K-7.1% | $613K-39.2% | $687K-39.7% |
| Long-Term Debt | $4.9M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $2.6M | $4.2M+57.5% | $3.4M+643.2% | $7.1M+66.4% | $4.1M-50.2% | $2.7M-28.9% | $452K-94.7% | $4.2M-68.3% |
| Retained Earnings | -$432.1M | -$428.4Mn/m | -$425.5Mn/m | -$421.3Mn/m | -$417.1Mn/m | -$413.6Mn/m | -$410.9Mn/m | -$406.8Mn/m |
Not reported in any period shown, so not listed: Inventory, Goodwill.
IMNN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2710-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M | -$3.0Mn/m | -$4.0Mn/m | -$3.7Mn/m | -$4.4Mn/m | -$3.0Mn/m | -$2.8Mn/m | -$4.4Mn/m |
| Depreciation & Amortization | $67K | $70K-6.7% | $70K+5.0% | $75K+101.6% | $75K+16.8% | $75K+9.8% | $67K-5.1% | $37K-48.0% |
| Stock-Based Compensation | N/A | N/A | $549K+168.2% | N/A | N/A | N/A | $205Kn/m | N/A |
| Capital Expenditures | $2K | N/A | N/A | $4K-75.9% | $0-100.0% | $17Kn/m | $260K+2108.9% | $15Kn/m |
| Free Cash Flow | -$3.2M | N/A | N/A | -$3.7Mn/m | -$4.4Mn/m | -$3.0Mn/m | -$3.1Mn/m | -$4.4Mn/m |
| Investing Cash Flow | -$2K | N/A | N/A | -$4Kn/m | $0n/m | -$17K-100.2% | -$260K-110.9% | -$15Kn/m |
| Financing Cash Flow | $419K | $10.2M+110.6% | -$2K-101.7% | $7.2Mn/m | $5.0M | $4.8M | $106K | -$3K-110.8% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
IMNN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2710-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -143.0% | -67.2%+35.9pp | -126.5%+781.1pp | -59.8%+35.8pp | -84.0%-24.9pp | -103.0%+25.0pp | -907.6%-849.6pp | -95.6%-59.1pp |
| Return on Assets | -31.2% | -18.8%+12.4pp | -53.0%+6.8pp | -34.4%+7.4pp | -38.1%-4.5pp | -31.2%+18.2pp | -59.8%-25.4pp | -41.8%-19.4pp |
| Current Ratio | 1.38 | 1.82+0.5x | 1.59+0.7x | 2.32+0.6x | 1.73-0.6x | 1.30-0.2x | 0.88-1.6x | 1.67-0.8x |
| Debt-to-Equity | 1.86 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | 3.58 | 2.58+0.3x | 1.39-12.8x | 0.74-0.5x | 1.20+0.4x | 2.30+0.7x | 14.18+13.5x | 1.29+0.7x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Imunon, Inc. IMNN | FY2026 | N/A | N/A | N/A | $3.8M | — |
| Xenetic Biosciences, Inc. XBIO | FY2025 | $3.0M | -$2.7M | -90.1% | $3.6M | 67/100 |
| CNS Pharmaceuticals, Inc. CNSP | FY2025 | N/A | -$15.9M | N/A | $6.6M | — |
| NuCana plc NCNA | FY2025 | N/A | -$39.5M | N/A | $3.5M | — |
| GRI Bio, Inc. GRI | FY2025 | N/A | -$12.0M | N/A | $2.8M | — |
| Liminatus Pharma, Inc. LIMN | FY2025 | N/A | N/A | N/A | $3.6M | — |
Where Imunon, Inc. Ranks
Frequently Asked Questions
Yes, Imunon, Inc. (IMNN) paid $0.15 per share in dividends during fiscal year 2026.
Imunon, Inc. (IMNN) had $15.0M in total assets as of fiscal year 2026, including both current and long-term assets.
Imunon, Inc. (IMNN) had a current ratio of 1.82 as of fiscal year 2026, which is generally considered healthy.
Imunon, Inc. (IMNN) had a liabilities-to-equity ratio of 2.58 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.
Imunon, Inc. (IMNN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $3.8M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Imunon, Inc. (IMNN) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $3.8M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.